35results about How to "Improve long-term survival" patented technology

The invention discloses a deep convolutional neural network-based lung cancer preventing self-service health cloud service system. The system comprises a convolutional neural network used for deep learning and training identification, a segmentation module which segments out a lung region from a CT image based on a full convolutional neural network, a deep convolutional neural network used for lung cancer diagnosis classification, and a self-service health cloud service platform used for performing early prevention and treatment according to an identified suspected lung cancer type. According to the system, the automation and intelligentization level of mobile internet-based lung cancer screening can be effectively improved, more citizens can know and participate in self-service health detection, assessment and guidance, the sensitivity, specificity and accuracy of early lung cancer screening and clinical diagnosis are improved, the lung cancer can be early discovered, early diagnosed and early treated, and the self-health management capability is enhanced.

The invention discloses a medicine for treating esophageal cancer. The medicine comprises the following raw materials in part by weight: 9 to 15 parts of astragalus, 10 to 15 parts of tangerine peel, 8 to 13 parts of cinnamomvine, 16 to 20 parts of stir-fried chicken's gizzard-membrane with vingar, 8 to 12 parts of muscone, 6 to 10 parts of scorpion, 5 to 8 parts of centipede, and 7 to 10 parts of borneol. Active pharmaceutical ingredients are prepared from the Chinese medicines, and capsule is prepared by mixing the active pharmaceutical ingredients and starch. The medicine can soothe liver and regulate qi, promote blood circulation and remove blood stasis, and clear heat and remove toxicity, has an anticancer and pain-relieving effect and does not have toxic or side effect; and clinical experiment proves that the medicine has a good effect of treating the esophageal cancer.

The invention discloses a nucleotide sequence and the application of an antigen-specific T cell receptor of the diffusive large B cell lymphoma. According to the RT-PCR genescan analysis, the TCR V Alpha 6 subfamilies in the peripheral blood of patients shows an obviously monoclonal state, and the V-N-J region, namely, the complementary determining region 3, where the PCR products conduct the sequence analysis of the specific TCR sequence, is a part recognizably bound to the antigenic specificity; the genescan analysis also shows that the TCR of the clonal T cell is a specific TCR produced due to the stimulus of the DLBL associated antigens, and is the basis and key for performing DLBL molecular targeted adoptive immunotherapy by means of the TCR transgenic technique. The nucleotide sequence of the specific TCR provides a significant basis for further carrying out lymphoma-specific cellular immunotherapy.

The invention provides a research method for identifying NK cell depletion in bone marrow of an AML patient and application of the research method. The method comprises the following steps: researching the maturity phenotype of NK cells in bone marrow when an AML patient relapses, and after determining the maturity of the NK cells, researching whether an inhibitory receptor is in overexpression on the NK cells when the AML patient relapses based on a receptor marker; and then, further researching the anti-tumor function change and multiplication capacity of the NK cells after recurrence of the AML patient and analyzing transcriptomics to identify the depletion phenomenon of the NK cells in the bone marrow of the AML patient. According to the method provided by the invention, a systematic research method is provided for NK cell depletion caused by leukemia for the first time, the NK cell depletion phenomenon of AML relapse patients after HSCT is proved, and meanwhile, high-frequency expression of NKG2A + NK cells is related to the relapse risk. Therefore, the research method provided by the invention has a huge application value in researching and judging whether the NK cells of the AML patient after HSCT are depleted or not.

The invention discloses a tissue engineering scaffold assembled by cell-loaded microgel as well as a preparation method and application thereof, and belongs to the technical field of biomedical engineering. Firstly, gel microspheres carrying bioactive substances prepared from a biological material with good biocompatibility by adopting a micro-flow liquid drop control technology are used to serve as basic units, and the cell-loaded gel microspheres are assembled into the tissue engineering scaffold by adopting a biological 3D printing mode. The micro-flow liquid drop control technology adopted by the invention can effectively shorten the preparation time of the cell-loaded gel microspheres, improve the preparation efficiency and ensure the cell activity; and the construction of a three-dimensional complex structure can be realized by utilizing a biological printing mode, and the application prospect is good.

The invention discloses a nucleic acid sequence of specific T cell receptor, which aims at the diffuse large B-cell lymphoma associated antigen. The RT-PCR gene scan analysis shows that the TCR V Alpha 23 subfamily in peripheral blood of DLBL patients has obvious monoclone; the V-N-J region of specific TCR sequence is discovered by the sequence analysis of the PCR product, which is the complementarity determining region 3; the complementarity determining region 3 is the specific recognition and binding site of the antigen, which shows that the TCR of the clonal T cell is the specific TCR generated by the stimulation of DLBL associated antigen. The invention is the basis and key for the DLBL molecular target adoptive immunotherapy through TCR transgenic technology.

The invention relates to a pharmaceutical composition for treating ischemic cerebral apoplexy and a preparation method and application thereof. The pharmaceutical composition for treating ischemic cerebral apoplexy is prepared from, by weight, 3-12 parts of NADPH and 0.5-8 parts of apocynin. NADPH and apocynin are applied jointly and act cooperatively in a specific proportion, and the pharmaceutical composition can reduce the cerebral infarction volume, significantly relieve the behavior disorder of cerebral ischemia mice, relieve encephaledema, improve the long-term survival capability of mice and enhance neurological function recovery; besides, the treatment effect of the pharmaceutical composition on ischemic cerebral apoplexy is much better than that of NADPH and apocynin which are applied independently on ischemic cerebral apoplexy, and a synergistic effect is achieved when NADPH and apocynin are applied jointly. Thus, the pharmaceutical composition has the effect of treating ischemic cerebral apoplexy and can serve as a potential drug for treating ischemic cerebral apoplexy.

The invention discloses an application of DYZ-9 in preparation of an anti-cardiac hypertrophy product. Compared with the prior art, the DYZ-9 provided by the invention has the following advantages: (1) the DYZ-9 studied in the invention can be synthesized by known methods, has a mature preparation process, can provide a reliable compound source, and has the advantages of a reliable substance source, low production costs, a novel mechanism of action and good market prospects; (2) the DYZ-9 has the effects of inhibiting phosphorylation of AKT and adenosine cyclophosphate effector element bindingprotein caused by isoproterenol (ISO), reducing the levels of myocardial hypertrophy markers ANP and BNP and a cardiac weight index, and improving myocardial hypertrophy; and (3) the DYZ-9 contributes to the research and development of the novel anti-cardiac hypertrophy drug, can bring direct economic benefits, and the drug can reduce the possibility of forming heart failure and malignant arrhythmia caused by further deterioration of the myocardial hypertrophy, and can save a lot of health expenses from a long-term perspective.

The invention discloses medical application of a benzenesulfonamide compound, and a pharmaceutical composition, and particularly relates to compounds shown as formulas I to V or pharmaceutically acceptable salts or solvates of the compounds. The compounds or the pharmaceutically acceptable salts or solvates of the compounds can be used for preparing STING inhibitors or drugs for inhibiting STING signal path activation and drugs for preventing or treating STING-mediated diseases.

The invention relates to a drug composition used for preventing hypertension complications and an application thereof. The drug composition provided by the invention is prepared from the following active ingredients in parts by weight: 22-28 parts of szechuan lovage rhizome, 15-20 parts of herba epimedii, 15-20 parts of rhizoma alismatis, 12-16 parts of radix angelicae pubescentis, 12-16 parts of mother chrysanthemum, 12-18 parts of polygala tenuifolia, 10-15 parts of semen plantaginis, 10-15 parts of Sichuan radix curcumae and 8-12 parts of grape seed. The drug composition provided by the invention can obviously reduce systolic pressure of a patient suffering from primary hypertension, effectively prevent various complications of a hypertensive patient and increase long-term survival rate of the patient.

The invention discloses a nucleotide sequence and the application of an antigen-specific T cell receptor of the diffuse large B cell lymphoma. According to the RT-PCR genescan analysis, the TCR V Alpha 23 subfamilies in the peripheral blood of patients shows an obviously monoclonal state, and the V-N-J region, namely, the complementary determining region 3, where the PCR products conduct the sequence analysis of the specific TCR sequence, is a part recognizably bound to the antigenic specificity; the genescan analysis also indicates that the TCR of the clonal T cell is a specific TCR produced due to the stimulus of the DLBL associated antigens, and is the basis and key for performing DLBL molecular targeted adoptive immunotherapy by means of the TCR transgenic technique. The nucleotide sequence of the specific TCR plays a significant role in further carrying out lymphoma-specific cellular immunotherapy.

The invention discloses a method for improving the construction survival rate of a coastal saline-alkali land protection forest. The method comprises the following steps: deeply digging in saline-alkali land to form planting pits; two layers of separation nets are laid on the bottom and the inner wall of the planting pit respectively, and the space between the two layers of separation nets is filled with a filtering layer; an isolation ring is placed in the isolation net, the space between the isolation net and the isolation ring is filled with saline-alkali land original soil mixed with a microbial agent, and the saline-alkali land original soil is aired for 1-2 days; saplings are planted, during planting, the saplings are planted in the isolation rings, the isolation rings are filled with the mixed matrix, and then the isolation rings are taken away. According to the method, the microbial agent and the filter layer are prepared and jointly used for construction of the coastal saline-alkali soil protection forest, salt outside the planting pits can be prevented from entering the periphery of the root system by using the filter layer, and the salt content around the plant root system can be reduced in combination with improvement measures of the microbial agent in the planting pits on saline-alkali soil; the damage of initial salinity of the coastal saline-alkali soil to the root system is reduced, and the long-term survival rate of the protection forest is improved.

The invention relates to the technical field of desert control and discloses a method for controlling desert sand. The method for controlling the desert sand comprises the following steps: S1, preparing fertilizer-retaining granules by a mold, preparing a hollow shell from solid fertilizer by the mold, opening a through hole in the shell in a run-through way and filling the hollow position with mist catching cotton; and S2, placing the fertilizer-retaining granules, mixing and stirring the fertilizer-retaining granules into the sand and enabling the fertilizer-retaining granules to be distributed at different depth of the sand. According to the technical scheme and by the method for controlling the desert sand, the problem that plants cannot grow in the existing desert continuously for a long time is solved.

The invention discloses chemotherapy immune gel as well as a preparation method and application thereof. The chemotherapy immune gel is fibrous protein hydrogel containing oxaliplatin and IPI549. And the IPI549 is a phosphocarnosine 3-kinase gamma inhibitor. The chemotherapy immune gel disclosed by the invention can be applied to treatment of residual tumors after microwave ablation, and through blocking of a PI3K gamma-dependent immunosuppression effect and enhancement of immunogenic tumor phenotypes brought by oxaliplatin treatment, strong systemic anti-cancer immunity can be realized, distant tumors and metastasis can be inhibited, the long-term survival rate can be increased, and the chemotherapy immune gel can be applied to treatment of the residual tumors after microwave ablation. And particularly, the medicine has a better treatment effect on tumor recurrence and metastasis caused by incomplete microwave ablation (iMWA).

The invention relates to a nitrendipine-containing medicine composition. Active ingredients of the nitrendipine-containing medicine composition comprise nitrendipine and polysaccharide sulfate, preferably, the weight ratio of nitrendipine to polysaccharide sulfate is 1 to (5 to 10). According to the medicine composition disclosed by the invention, all complicating diseases of hypertensive patientscan be effectively cooperatively prevented, a long-term survival rate of patients is increased, and meanwhile, the nitrendipine-containing medicine composition has a good prevention effect on heart failure for the hypertensive patients.

The invention discloses a nucleic acid sequence of specific T cell receptor, which aims at the diffuse large B-cell lymphoma associated antigen. The RT-PCR gene scan analysis shows that the TCR V Beta 13 subfamily in peripheral blood of DLBL patients has obvious monoclone; the V-NDN-J region of specific TCR sequence is discovered by the sequence analysis of the PCR product, which is the complementarity determining region 3; the complementarity determining region 3 is the specific recognition and binding site of the antigen, which shows that the TCR of the clonal T cell is the specific TCR generated by the stimulation of DLBL associated antigen. The invention is the basis and key for the DLBL molecular target adoptive immunotherapy through TCR transgenic technology. The specific TCR nucleic acid sequence provides important discovery for the further development of specific cellular immunotherapy of the lymphoma.

A pharmaceutical composition for treating ischemic stroke and a preparation method and use thereof. The active pharmaceutical ingredients of the pharmaceutical composition include: 0.05-20 parts by weight of NADPH, and 10-100 parts by weight of NAD+.

The application discloses a pharmaceutical composition for treating esophageal cancer. The pharmaceutical composition is an oral preparation prepared through the cooperation between Chinese medicinalmaterials and a pharmaceutically acceptable carrier. The Chinese medicinal materials are: cuttlebone, centipede, scorpion, ginseng root, common yam rhizome, dried ginger, tangerine peel, mongolian snakegourd root, danshen root, dwarf lilyturf tuber, house lizard, bulbus fritillariae thunbergii and pinellia tuber; and the parts by weight of the Chinese medicinal materials are: 11 to 15 parts of cuttlebone, 3 to 6 parts of centipede, 5 to 10 parts of scorpion, 3 to 5 parts of ginseng root, 9 to 12 parts of common yam rhizome, 5 to 8 parts of dried ginger, 9 to 15 parts of tangerine peel, 8 to 10parts of mongolian snakegourd root, 5 to 9 parts of danshen root, 8 to 10 parts of dwarf lilyturf tuber, 9 to 13 parts of house lizard, 3 to 7 parts of bulbus fritillariae thunbergii and 3 to 7 partsof pinellia tuber. While killing and inhibiting tumor cells, the pharmaceutical composition for treating esophageal cancer provided by the application can also enhance the immunity of the bodies of patients and the regulatory capability of the internal environment of the body and effectively protect and enhance the disease resistance of the body, thus increasing the long-term curative effect in treating esophageal cancer and the long-term survival rates of patients.